

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/714,389
Filing Date	November 13, 2003
First Named Inventor	Davin C. Dillon
Art Unit	1645
Examiner Name	
Attorney Docket No.	210121.491D1

ENCLOSURES (check all that apply)									
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement; Forms PTO-1449 (3 Sheets) A Cited References Certified Copy of Priority Document(s) Response to Missing Parts under 37 CFR 1.52 or 1.53 Response to Missing Parts/Incomplete Application	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD	After Allo Commun Appeal C Board of Interfered Appeal C TC (Appear Reply Br Proprieta Status Le	communication to Appeals and nees Communication to eal Notice, Brief, iref) ary Information etter Receipt Postcard aclosure(s) (please						
	tual Property Law Group PLLC	Custo	mer Number						
Signature Chilic	Unato								
Printed Name Julie A. Urva	ter, Ph.D., Patent Agent								
Date September 1	, 2005 Reg. N	lo. 50,46	1						
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Signature									
Typed or printed name Lawrence Teague Date: September 1, 200 This collection of information is required by 37 CER 1.5. The information is required to obtain or retain a henefit by the public which is to file (and by the US)									

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. F:\Pat\PTOSB21.doc

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

September 1, 2005 Lawrence Teague

Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Davin C. Dillon et al.

Application No.

10/714,389

Filed

November 13, 2003

For

COMPOSITIONS AND METHODS FOR THE

THERAPY AND DIAGNOSIS OF BREAST CANCER

Art Unit

1645

Docket No.

: 210121.491D1

Date

: September 1, 2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. This application is a divisional and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/778,320, filed February 6, 2001; which is a continuation-in-part of prior Application No. 09/571,025, filed May 15, 2000, now abandoned; which is a continuation-in-part of prior Application No. 09/545,068, filed April 7, 2000, now abandoned; which is a continuation-in-part of prior Application No. 09/523,586, filed March 10, 2000, now abandoned; which is a continuation-in-part of prior Application No. 09/510,662, filed February 22, 2000, now abandoned; which is a continuation-in-part of prior Application No. 09/451,651, filed November 30, 1999, now issued as U.S. Patent 6,489,101. The references listed on page 1 of the

attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies of these references will be provided upon request. However, the 20 references listed on pages 2-3 of the attached Forms PTO-1449 were not made of record in these prior applications. Accordingly, copies of these are enclosed herewith, though copies of the cited U.S. published patent applications are not included among them.

As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Julie A. Urvater, Ph.D., Patent Agent

Registration No. 50,461

JAU:ljt

Enclosures:

Postcard Transmittal Form Forms PTO-1449 (3 Sheets) Cited References (18)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\686231

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV.7-80) PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. APPLICATION NO.							
				210121.491D1 10/714,389 01A						
INFORMATION DISCLOSURE STATEMENT			ENT	Davin C. Dillon et al.			/ ₋ s	Ep ,	` <u> </u>	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			EN I	FILING DATE	· 	GRO	UP ART HIT	OB.	3	
•					November 13, 2003		164	12	1000	
U.S. PATENT 1				DOCUMENTS		101	<u></u>	PEMARK C	METICAL .	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME				FILING DATE IF APPROPRIATE	
	АА	5,654,172	08/05/97	Li et al.		435		69.1		
,	AB									
			FOREI	GN PATE	NT DOCUMENTS					
		DOCUMENT NUMBER	DATE		COUNTRY				TRANS YES	LATION NO
	AC	WO 96/06862	03/07/96	WIPO						
	AD	WO 97/25431	07/17/97	WIPO	·					
	AE	WO 99/14230	03/25/99	WIPO	WIPO					
	AF	WO 99/25877	05/1999	WIPO	WIPO					
	AG	WO 99/33869	09/08/99	WIPO					<u>. </u>	
	АН	WO 99/37775	07/29/99	WIPO						
	Al	WO 00/12758	03/2000	WIPO						
		0	THER ART	(Including Autho	or, Title, Date, Pertinent Pages, E	Etc.)				
	LΑ				Anatomy: Correlation of vel Gene Product Di12."	-	_			Ì
	AK	Diatchenko et	Carcinomas with Expression of the Novel Gene Product Di12," <i>Oncogene 16</i> :327-333, 1998. Diatchenko et al., "Suppression subtractive Hybridization: A Method for Generating Differentially							
			Regulated or Tissue-Specific cDNA Probes and Libraries," <i>PNAS 93</i> :6025-6030, June 1996. Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system:							
	AL			-	ved interleukin-4-depend		•		-	9_199
		July 1, 1994.		ast con-doll	Tod Interreukin-4-depend	ioin co	1111	c, Dioou o	,(1).10	× 177,
	AM		Hedblom and Kirkness, "A novel class of GABA _A receptor subunit in tissues of the reproductive							
			-		emistry 272(24):15346-1					
	AN		Lee et al., "Positive Selection of Candidate Tumor-Suppressor Genes by Subtractive Hybridization," PNAS 88:2825-2829, April 1991.							
	AO		Porter-Jordan and Lippman, "Overview of the biologic markers of breast cancer," Breast Cancer						icer	
			8(1):73-100, February 1994.						v cf	
	AP	Schlom et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," <i>Breast Cancer Research and Treatment 38</i> (1):27-39, 1996.							y OI	
EXAMINE	R	<u> </u>			DATE CONSIDERED					
* EXAMINI					nformance with MPEP 609. Draw with next communication to appli		ough c	itation if not in		

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. APPLICATION NO. 210121.491D1 10/714,389			<u> </u>			
			APPLICANTS 10/714,389							
INFORMATION DISCLOSURE STATEMENT			Davin C. Dillon et al.					l		
(Use several sheets if necessary)				FILING DATE	•	GPO	UP ART UNIT			
(Ose several sneed it necessary)						164				
				November 13, 2003		104	13			
*EXAMINER		DOCUMENT NUMBER	DATE DATE	PAIENI	DOCUMENTS NAME	CLA	cc	SUBCLASS	FILING	G DATE
INITIAL				G1 1			.33		IF APPR	OPRIATE
	BA	2003/0022334	01/30/03	Glucksma		435		189		
	BB	2003/0027988	02/06/03	Baker et a	ıl.	530		350		
	BC									
	BD								-	
	BE									
	BF	-						ļ		
	BG									
	вн									
	Bl						_			
	ВЈ									
			FOREI	GN PATE	NT DOCUMENTS					
		DOCUMENT DATE			COUNTRY				TRANS YES	LATION NO
<u> </u>	вк	WO 99/00408	01/07/99	WIPO						
	BL	WO 00/36107	06/22/00	WIPO						
	ВМ	WO 00/61756	10/19/00	WIPO						
	BN	WO 01/40269	06/07/01	WIPO						
	во	WO 01/51628	07/19/01	WIPO						
		0'	THER ART	(Including Autho	or, Title, Date, Pertinent Pages, E	Etc.)				
	ВР	· · · · r · · · · · · · · · · · · · · · · · · ·			AF100759, July 8, 199					
	BQ	GenBank Database, Accession No. AJ131016, February 4, 2000.								
	BR	GenBank Database, Accession No. AL135960, February 3, 2000.								
EXAMINE	i R				DATE CONSIDERED					
* EXAMIN	ER:				nformance with MPEP 609. Draw		ough c	itation if not in		

Sheet <u>3</u> of <u>3</u>

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV.7-80) PATENT AND TRADEMARK OFFICE -				ATTY. DOCKET NO. APPLICATION NO. 210121.491D1 10/714,389					
			APPLICANTS D C. D						
INFORMATION DISCLOSURE STATEMENT			Davin C. Dillon et al.						
(Use several sheets if necessary)				FILING DATE		UP ART UNIT			
					November 13, 2003	164	13		
			U.S.	. PATENT	DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME CLASS SUBCLASS			SUBCLASS	FILING DATE IF APPROPRIATE	
	CA		FORE	ICN DATES					
		T BOOM BY	FOREI	IGN PATER	NT DOCUMENTS			TDANE	A TION
		DOCUMENT NUMBER	DATE		COUNTRY			YES	NO
	СВ	WO 01/51638	07/19/01	WIPO					
	СС	WO 01/90334	11/29/01	WIPO		·····	·		
	CD	WO 01/93983	12/13/01	WIPO					
	CE.								
	CF								
		O	THER ART	(Including Author	or, Title, Date, Pertinent Pages, E.	tc.)			
	CG	GenBank Da	itabase, Acc	ession No.	AL356793, November	29, 2001.			
	СН	Genseq Data	Genseq Database (Thomason Derwent), Accession No. AAL08649, December 7, 2001.						
	CI	Genseq Data	Genseq Database (Thomason Derwent), Accession No. AAL18673, December 7, 2001.						
	CJ	Genseq Data	Genseq Database (Thomason Derwent), Accession No. AAL23934, December 7, 2001.						١.
	СК	Genseq Data	Genseq Database (Thomason Derwent), Accession No. AAL24582, December 7, 2001.						
		C. D.							
	CL	Genseq Data	Genseq Database (Thomason Derwent), Accession No. AAW92654, April 30, 1999.						
	СМ		Xu, J. et al., "Identification of differentially expressed genes in human breast tumor using						
			subtraction and microarray," <i>Proceedings of the American Association for Cancer Research</i> 40: 319, Abstract #2115, March 1999.						
	CN								
EXAMINE	il				DATE CONSIDERED				
* EXAMINI	ER: i		ered, whether or no		nformance with MPEP 609. Draw	line through o	itation if not in		